Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Mutation Research|July 4, 2006
SFTG international collaborative study on in vitro micronucleus test I. General conditions and overall conclusions of the studyElisabeth Lorge, Veronique Thybaud, Marilyn J Aardema, et al.
Mutation Research|June 27, 2006
SFTG international collaborative study on in vitro micronucleus test V. Using L5178Y cellsJo Oliver, Jean-Roch Meunier, Takumi Awogi, et al.
Mutation Research|June 13, 2006
SFTG international collaborative study on in vitro micronucleus test II. Using human lymphocytesM Gillian Clare, Giocondo Lorenzon, Leslie C Akhurst, et al.
Plos One|September 24, 2014
Targeting of alpha-v integrins reduces malignancy of bladder carcinomaGeertje van der Horst, Lieke Bos, Maaike van der Mark, et al.
Mutation Research|June 27, 2006
SFTG international collaborative study on in vitro micronucleus test III. Using CHO cellsMarilyn J Aardema, Ronald D Snyder, Carol Spicer, et al.
Cancers|March 16, 2019
The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma ModelsGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Neoplasia (New York, N.Y.)|June 17, 2011
Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancerGeertje van der Horst, Christel van den Hoogen, Jeroen T Buijs, et al.
Cancers|December 31, 2025
RETRACTED: Gravina et al. The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. <i>Cancers</i> 2019, <i>11</i>, 359Giovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Mutation Research|June 20, 2006
SFTG international collaborative study on in vitro micronucleus test IV. Using CHL cellsAkihiro Wakata, Atsuko Matsuoka, Kohji Yamakage, et al.
Investigational New Drugs|January 22, 2016
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignanciesGeert A Cirkel, Bojana Milojkovic Kerklaan, Frédéric Vanhoutte, et al.
Pageof 1